免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于树突状细胞的实体瘤免疫治疗
英文原题：Dendritic Cell-Based Immunotherapy for Solid Tumors.
查看英文原题
Dendritic Cell-Based Immunotherapy for Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
树突状细胞（DC）是连接固有免疫和适应性免疫的关键抗原呈递细胞，通过激活T细胞、NK细胞和NKT细胞影响肿瘤微环境，并可直接杀伤肿瘤细胞。目前正在探索其作为黑色素瘤、乳腺癌、前列腺癌、脑癌和血液系统恶性肿瘤等癌症的免疫治疗方法，迄今已有超过300项临床试验。瘤内注射因其直接效应而显示出前景。唯一获FDA批准的DC疗法sipuleucel-T可提高前列腺癌患者的生存期。更多DC试验正在进行中，通常将DC与其他可用的免疫疗法联合使用。早期疾病正成为DC治疗的新兴靶点。需要进一步研究以优化这些方法。
展开英文摘要原文
Dendritic cells (DCs) are key antigen-presenting cells that connect innate and adaptive immunity, influencing tumor microenvironments by activating T cells, NK, and NKT cells, and directly killing tumor cells. They are being explored as immunotherapies in cancers like melanoma, breast, prostate, brain, and blood cancers with over 300 clinical trials to date. Intratumoral injection shows promise for its direct effects. The only FDA-approved DC therapy, sipuleucel-T, increases survival in prostate cancer.
Further DC trials are ongoing, often combining DCs with other available immunotherapies. Early-stage disease is an emerging target for DC therapy.
Further research is needed to optimize these approaches.
论文信息
- 作者
- Baumrucker C、Relation T、Czerniecki BJ
- 第一作者单位
- Department of Surgery, George Washington University, Washington, DC 20037, USA.United States
- 通讯作者单位
- Department of Breast Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: Brian.Czerniecki@moffitt.org.United States
- 文献类型
- 综述
- 期刊
- Surgical oncology clinics of North America2026 Apr
- 原文标识
- PubMed 41903989 · DOI 10.1016/j.soc.2025.10.005